

# Optimal Dose of Hypertonic Saline/Dextran in Hemorrhaged Swine

## Originally scheduled for publication in the Combat Fluid Resuscitation Supplement\*

Charles E. Wade, PhD, Michael A. Dubick, PhD, and J. J. Grady, PhD for the HSD Development Group

**Background:** Hypertonic saline/dextran (HSD) fluid resuscitation has been demonstrated to be effective in alleviating the adverse effects of hemorrhagic hypotension. The optimal dose of HSD has not been defined.

**Methods:** The comparative effectiveness of various dosages of HSD for the treatment of severe hemorrhage was investigated in conscious swine bled 46 mL/kg over 15

minutes, a lethal procedure. Five minutes after the completion of hemorrhage, animals were treated with 1, 2, 4, or 11.5 mL/kg HSD and observed over the next 96 hours.

**Results:** The 11.5-mL dose resulted in 100% survival, which was statistically superior to the 1- and 2-mL doses but not the 4-mL dose. Survival incidences with 4, 2, and 1 mL/kg were 83%, 64%, and 13%, respectively.

**Conclusion:** In terms of survival time, the 11.5- and 4-mL/kg doses were not significantly different. Therefore, optimum resuscitative effectiveness of HSD is achieved within the dose range of 4 to 11.5 mL/kg.

**Key Words:** Survival, Fluid resuscitation, Injury, Hypotension

*J Trauma.* 2003;55:413–416.

Hypertonic saline/dextran (HSD) is now recognized as a highly effective resuscitation solution for the treatment of life-threatening hemorrhagic hypotension. The efficacy of HSD has been demonstrated in numerous animal models and in a number of clinical studies.<sup>1–17</sup> Administration of HSD (7.5% NaCl in 6% Dextran) corrects many of the hemodynamic and metabolic sequelae of hemorrhage, ultimately leading to an improvement in survival. Doses ranging from 2.5 to 11.5 mL/kg of HSD have been used.<sup>2,18</sup> Most of the studies in animals and humans, however, have used a dose

of approximately 4 mL/kg of HSD. This dose has been shown to be efficacious, but was selected arbitrarily. As noted recently by Stern et al.,<sup>19</sup> to date there have been no definitive studies to determine the optimum dosage of HSD. The present study was conducted to address this question, presenting experimental data on the duration and incidence of survival after the administration of 1, 2, 4, or 11.5 mL/kg of HSD to conscious pigs that were subjected to an otherwise lethal controlled hemorrhage insult.<sup>2,20</sup>

## MATERIALS AND METHODS

All experimental procedures were reviewed and approved by the Institutional Animal Care and Use Committee at the Letterman Army Institute of Research, where the study was performed. Five days before experimental use, immature barrows and gilts, obtained from a commercial breeder (J.G. Boswell, Corcoran, CA) weighing 19 to 25 kg, were premedicated with 0.09 mg/kg atropine sulfate, 2.2 mg/kg ketamine hydrochloride, and 2.2 mg/kg xylazine administered intramuscularly. Halothane anesthesia was then induced (0.05% halothane, 1.0% methoxyflurane, nitrous oxide, and oxygen), and catheters were implanted under aseptic conditions in the left external jugular vein and descending aorta for infusion of the treatment solutions and blood withdrawal, respectively. The health and well-being of the animals were periodically assessed during the recovery period.

On the day of study, after an overnight fast with water available, each pig was transported to the laboratory and placed in a holding cage that restricted its movements. The conscious animal was then subjected to a 46-mL/kg hemorrhage over a 15-minute period, an insult that is fatal in over 87% of untreated pigs.<sup>2,20</sup> The animal was randomly assigned

Submitted for publication January 21, 2002.

Accepted for publication January 6, 2003.

Copyright © 2003 by Lippincott Williams & Wilkins, Inc.

From BioPhausia AB (C.E.W.), Uppsala, Sweden, U.S. Army Institute of Surgical Research (M.A.D.), San Antonio, and Department of Preventive Medicine and Community Health, University of Texas Medical Branch (J.J.G.), Galveston, Texas.

\*This article was mistakenly omitted from the Combat Fluid Resuscitation Supplement, which was published in May 2003. The editorial office regrets the omission.

The opinions and assertions contained herein are the private views of the authors and are not to be construed as official or as reflecting the views of the Department of the Army or the Department of Defense. This work was performed at the former Letterman Army Institute of Research, Presidio of San Francisco, California. The results and conclusions contained in this report were extracted from data from a number of studies conducted during the developmental effort on hypertonic saline solutions at Letterman Army Institute of Research. Dr. Wade is a paid consultant for BioPhausia AB. Dr. Wade holds stock in Trauma Products Inc., which has licensed the rights for HSD in the United States from the University of California.

Supported by BioPhausia AB, which markets Hypertonic Saline Dextran in Europe under the name RescueFlow.

Address for reprints: Charles Wade, MD, 109 Pearl Street, Sausalito, CA 94965; email: edawc@aol.com.


DOI: 10.1097/01.TA.0000057247.02378.5E

## Report Documentation Page

*Form Approved  
OMB No. 0704-0188*

Public reporting burden for the collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden, to Washington Headquarters Services, Directorate for Information Operations and Reports, 1215 Jefferson Davis Highway, Suite 1204, Arlington VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to a penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.

1. REPORT DATE <b>01 SEP 2003</b>	2. REPORT TYPE <b>N/A</b>	3. DATES COVERED <b>-</b>		
4. TITLE AND SUBTITLE <b>Optimal dose of hypertonic saline dextran (HSD) in hemorrhaged swine.</b>		5a. CONTRACT NUMBER		
		5b. GRANT NUMBER		
		5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) <b>Wade C. E., Dubick M. A., Grady J. J.,</b>		5d. PROJECT NUMBER		
		5e. TASK NUMBER		
		5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) <b>United States Army Institute of Surgical Research, JBSA Fort Sam Houston, TX 78232</b>		8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES)		10. SPONSOR/MONITOR'S ACRONYM(S)		
		11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION/AVAILABILITY STATEMENT <b>Approved for public release, distribution unlimited</b>				
13. SUPPLEMENTARY NOTES				
14. ABSTRACT				
15. SUBJECT TERMS				
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	
a. REPORT <b>unclassified</b>	b. ABSTRACT <b>unclassified</b>	c. THIS PAGE <b>unclassified</b>	<b>SAR</b>	18. NUMBER OF PAGES <b>4</b>
				19a. NAME OF RESPONSIBLE PERSON



**Fig. 1.** Percent survival of hemorrhaged swine treated with varying doses of HSD.


to one of four groups and, 5 minutes after the completion of hemorrhage, treated with either 1, 2, 4, or 11.5 mL/kg of HSD, administered by rapid intravenous (jugular catheter) infusion. The resuscitation solution, 7.5% NaCl in 6% Dextran 70, was provided by Pharmacia, Inc. (Sweden; Batch I-328510). After resuscitation, the animals were observed for 3 hours and then returned to their cages, provided free access to food and water, and observed regularly over the next 96 hours. If death occurred, the duration of survival was recorded.

### Statistical Analysis

Between-group resuscitative effectiveness in terms of survival versus nonsurvival during the 96-hour observation period was evaluated with a  $\chi^2$  test followed by Marascuilo's method of multiple comparisons.<sup>21</sup> Between-group resuscitative effectiveness in terms of survival time before death (or 96 hours if death did not occur) was evaluated with a generalized Wilcoxon test, after appropriate adjustments for multiple comparisons. Differences between mean values were considered significant when  $p < 0.05$ . Values in the text are means  $\pm$  SEM. We used the PROBIT procedure in SAS<sup>21</sup> to conduct a quantal assay of the data to estimate the optimal dose for survival rates of 90% and 95%. The logistic distribution was used to estimate the parameters. A goodness-of-fit statistic is also reported.

### RESULTS

All pigs resuscitated with 11.5 mL/kg of HSD ( $n = 14$ ) were alive at the end of the 96-hour observation period, and resuscitative effectiveness of this dose was significantly superior to doses of 1 and 2 mL/kg, at least in terms of survival enhancement (Fig. 1). There was no significant difference in survival between 11.5 and 4 mL/kg. Resuscitation with 4 mL/kg of HSD ( $n = 18$ ), and to a lesser extent 2 mL/kg ( $n = 14$ ), also enhanced survival; respectively, 83% and 64% of the animals in these groups were alive at the end of the



**Fig. 2.** Percent survival over time of swine treated with varying doses of HSD. Animals were followed for 96 hours and no additional deaths occurred.

observation period. In contrast, a 1-mL/kg dose ( $n = 15$ ) was followed by only 13% survival, a value that was equal to that observed in this animal model when no resuscitative treatment was provided.<sup>2</sup>

Between-group comparisons of survival time after resuscitation also revealed significantly different dose effects (Fig. 2). As previously indicated, all animals treated with the 11.5-mL/kg dose survived the 96-hour observation period. Resuscitation with 4 mL/kg of HSD resulted in a mean survival time of  $80 \pm 10$  hours, a value that was not significantly different from that observed after the 11.5-mL/kg dose. Survival time for the 2-mL/kg dose was  $67 \pm 13.8$  hours, significantly less than the 11.5-mL/kg dose, but not different from the time observed with the 4-mL/kg dose. Animals receiving the 1-mL/kg dose survived  $13 \pm 8.7$  hours, a value that was significantly less than observed with all other doses.

A quantal assay of the data estimated the optimal dose for 90% survival rate at 4.2 mL/kg (95% confidence interval, 3.28–7.30 mL/kg) and for 99% survival at 6.5 mL/kg (95% confidence interval, 4.82–12.75 mL/kg). A goodness-of-fit test based on the Pearson  $\chi^2$  suggested no lack of fit ( $p = 0.22$ ) for the model.

### DISCUSSION

On the basis of the data presented here, it appears that severely hemorrhaged swine can be effectively resuscitated with HSD at dosage levels of 3.3 to 7.3 mL/kg. The 4-mL/kg dose, although not 100% effective, did provide significant improvements in both the incidence and duration of survival

compared with lower doses and no treatment. Wade et al.<sup>3</sup> have previously shown that 4 mL/kg of HSD, in swine hemorrhaged over a longer period to end mean blood pressures similar to the model in the present study,<sup>2</sup> produced a survival rate of 66%, appreciably less than the 83% survival rate of the same dose in the present study. Velasco et al.<sup>4</sup> have reported a survival incidence of 92% in hemorrhaged anesthetized dogs that were administered 6 mL/kg of HSD. Stern et al.,<sup>19</sup> using a lethal model of uncontrolled hemorrhage in anesthetized swine, found administration of 8 mL/kg of HSD to improve survival to 75%, if the rate of infusion was slow. Thus, the experimental model and rate of infusion as well as the dose of HSD can influence the interpretation of survival data as indicated by studies of uncontrolled hemorrhage. In the present study, a consistent hemorrhage model was used that mimicked rapid blood loss and early (within 20 minutes of injury) fluid administration. The present study suggests that the dose of 4 mL/kg alone may not be fully effective for ensuring survival but does extend survival time after hemorrhage.

In the present animal studies, HSD was the only treatment solution administered. In the clinical setting, the administration of HSD has been followed by conventional fluids such as lactated Ringer's solution or normal saline.<sup>7-14</sup> The clinical dose presently recommended for HSD is 250 mL administered intravenously with additional fluids as deemed clinically necessary. This dose was selected arbitrarily on the basis of a number of factors. The first factor was the minimum fluid volume to be carried by military medics using available approved packaging (a 250-mL bag of solution that when administered to a 70-kg human was a dose of 3.6 mL/kg).<sup>22</sup> The second factor was based on the assumption that a greater dose of HSD would result in hypernatremia and neurologic dysfunction (the dose was calculated to maintain plasma sodium concentrations within a safe range).<sup>6,23,24</sup> The body weights of patients in previous studies of HSD have not been reported. From data records, we determined that the median body weight of patients enrolled in these studies was 72 kg (n = 519), with the resultant dose of HSD being approximately 3.5 mL/kg.<sup>16</sup> In addition, in the majority of these patients, plasma sodium concentrations, although elevated, were within the desired safety range.<sup>7-14</sup> After treatment with HSD, 90% of the patients had plasma sodium levels less than 155 mmol/L.<sup>10,16</sup> A dose of 250 mL of HSD is effective in expanding blood volume<sup>25</sup> to a greater extent than an equal volume of normal saline solutions and in correcting the hypotension observed in trauma patients.<sup>12</sup> The presently recommended clinical dose of HSD (250 mL), therefore, is within the effective range for expanding blood volume and correcting blood pressure in the patient with traumatic injuries and hypotension. However, this dosage, if administered as the sole resuscitation solution, may be below the level that could ensure a maximal advantage for survival.

## ACKNOWLEDGMENT

We wish to acknowledge that this was a team effort involving numerous individuals.

## REFERENCES

1. Maningas PA, DeGuzman LR, Tillman FJ, et al. Small-volume infusion of 7.5% NaCl in 6% Dextran 70 for the treatment of severe hemorrhagic shock in swine. *Ann Emerg Med.* 1986;15:1131-1137.
2. Maningas PA, Bellamy RF. Hypertonic sodium chloride solutions for the prehospital management of traumatic hemorrhagic shock: a possible improvement in the standard of care? *Ann Emerg Med.* 1986;15:1411-1414.
3. Wade CE, Hannon JP, Bossone CA, et al. Resuscitation of conscious pigs following hemorrhage: comparative efficacy of small-volume resuscitation. *Circ Shock.* 1989;29:193-204.
4. Velasco IT, Rocha e Silva M, Oliveira MA, Oliveira MA, Silva RIN. Hypertonic and hyperoncotic resuscitation from severe hemorrhagic shock in dogs: a comparative study. *Crit Care Med.* 1989;17:261-264.
5. Stern SA, Jwayyed S, Dronen SC, Wang X. Resuscitation of severe uncontrolled hemorrhage: 7.5% sodium chloride/6% dextran 70 vs 0.9% sodium chloride. *Acad Emerg Med.* 2000;7:847-856.
6. Dubick MA, Wade CE. A review of the efficacy and safety of 7.5% NaCl/6% dextran 70 in experimental animals and in humans. *J Trauma.* 1994;36:323-330.
7. Maningas PA, Mattox KL, Pepe PE, Jones RL, Feliciano DV, Burch JM. Hypertonic saline-dextran solution for the prehospital management of traumatic hypotension: a preliminary report. *Am J Surg.* 1989;177:528-533.
8. Vassar M, Perry C, Holcroft J. Analysis of potential risks associated with 7.5% sodium chloride resuscitation of traumatic shock. *Arch Surg.* 1990;125:1309-1315.
9. Vassar MJ, Perry CA, Gannaway WL, Holcroft JW. 7.5% sodium chloride/dextran for resuscitation of trauma patients undergoing helicopter transport. *Arch Surg.* 1991;126:1065-1072.
10. Mattox KL, Maningas PA, Moore EE, et al. Prehospital hypertonic saline/dextran infusion for post-traumatic hypotension: the USA multicenter study. *Ann Surg.* 1991;213:482-491.
11. Younes RN, Aun F, Accioly CQ, Casale LPL, Szajn bok I, Birolini D. Hypertonic solutions in the treatment of hypovolemic shock: a prospective, randomized study in patients admitted to the emergency room. *Surgery.* 1992;111:70-72.
12. Vassar M, Perry CA, Holcroft JW. Prehospital resuscitation of hypotensive trauma with 7.5% NaCl versus 7.5% NaCl with added dextran: a controlled trial. *J Trauma.* 1993;34:622-633.
13. Vassar M, Fischer RP, O'Brien P, et al. A multicenter trial for resuscitation of injured patients with 7.5% NaCl: the effect of added dextran. *Arch Surg.* 1993;128:1003-1013.
14. Younes RN, Aun F, Ching CT, et al. Prognostic factors to predict outcome following the administration of hypertonic/hyperoncotic solution in hypovolemic patients. *Shock.* 1997;7:79-83.
15. Wade CE, Grady JJ, Kramer GC, Younes RN, Gehlsen K, Holcroft JW. Individual patient cohort analysis of the efficacy of hypertonic saline/dextran in patients with traumatic brain injury and hypotension. *J Trauma.* 1997;42:S61-S65.
16. Wade CE, Grady JJ, Kramer GC, Younes RN, Fabian T, Holcroft JW. Meta-analysis of the efficacy of HSD in patients with hypotension due to traumatic injury. *Surgery.* 1997;122:609-616.
17. Wade CE, Grady JJ, Kramer G. Efficacy of hypertonic saline dextran (HSD) in patients with traumatic hypotension: meta-analysis of individual patient data. *Acta Anaesthesiol Scand.* 1997;110:77-79.
18. Perron PR, Walsh JC, Gunther RA, Holcroft JW, Kramer GC. Resuscitation of hemorrhage (43 ml/kg) using less than 1 ml/kg of saturated NaCl/Dextran solution. *Circ Shock.* 1987;21:321.

19. Stern SA, Kowalenko T, Younger J, Wang X, Dronen SC. Comparison of the effects of bolus vs. slow infusion of 7.5% NaCl/6% dextran-70 in a model of near-lethal controlled hemorrhage. *Shock*. 2000;14:616–622.
20. Traverso LW, Moore CC, Tilliman FJ. A clinically applicable exsanguination shock model in swine. *Circ Shock*. 1984;12:1–7.
21. SAS Institute, Inc. *SAS/STAT Users Guide*. Vol 1, 2, and 3, Version 8. Cary, NC: SAS Institute; 2000.
22. Pope A, French G, Longnecker DE. *Fluid Resuscitation*. Washington, DC: National Academy Press; 1999.
23. Mattar JA. Hypertonic and hyperoncotic solutions in patients. *Crit Care Med*. 1989;17:297–298.
24. Holcroft JW, Vassar MJ, Turner JE, Derlet RW, Kramer GC. 3% NaCl and 7.5% NaCl/Dextran 70 in the resuscitation of severely injured patients. *Ann Surg*. 1987;206:279–288.
25. Töllofsrud S, Tonnessen T, Skraastad O, Noddeland H. Hypertonic saline and dextran in normovolaemic and hypovolaemic healthy volunteers increases interstitial and intravascular fluid volumes. *Acta Anaesthesiol Scand*. 1998;42:145–153.